[go: up one dir, main page]

AR052568A1 - Derivados de pirazolo -pirimidina como antagonstas de mglur2 - Google Patents

Derivados de pirazolo -pirimidina como antagonstas de mglur2

Info

Publication number
AR052568A1
AR052568A1 ARP060100412A ARP060100412A AR052568A1 AR 052568 A1 AR052568 A1 AR 052568A1 AR P060100412 A ARP060100412 A AR P060100412A AR P060100412 A ARP060100412 A AR P060100412A AR 052568 A1 AR052568 A1 AR 052568A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
halogen
haloalkyl
cycloalkyl
Prior art date
Application number
ARP060100412A
Other languages
English (en)
Inventor
Silvia Gatti Mcarthur
Erwin Goetschi
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR052568A1 publication Critical patent/AR052568A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto que se ajusta a la formula (1) en la que a se elige entre el grupo formado por las formulas (2), Ra es H, halogeno o alquilo C1-6; R1 es H, halogeno, alcoxi C1-6, alquilo C1-6, haloalquilo C1-6, haloalcoxi c1-6; R2 es halogeno, haloalquilo C1-6; R3 es alquilo c1-6 opcionalmente sustituido por hidroxi; o es NRbRc, en el que Rb y Rc se eligen con independencia entre sí entre el grupo formado por: H, cicloalquilo C3-8, arilo, heteroarilo que tiene de 5 a 12 átomos en el anillo y alquilo C1-6 que está opcionalmente sustituido por uno o varios sustituyentes elegidos entre el grupo formado por halogeno, hidroxi, cicloalquilo C3-8, arilo, heteroarilo que tiene de 5 a 12 átomos en el anillo y -NRbRc, en el que Rb y Rc se eligen con independencia entre sí entre el grupo formado por H y alquilo C1-6; o Rb y Rc junto con el átomo de N al que están unidos pueden formar un grupo heterocíclico opcionalmente sustituido que contiene de 5 a 12 átomos en el anillo, en el que los sustituyentes se eligen entre el grupo formado por halogeno, hidroxi, alquilo C1-6 y haloalquilo C1-6; R4 es H, alquilo C1-6 lineal, haloalquilo C1-6 o cicloalquilo C3-4; así como las sales farmacéuticamente aceptables del mismo.
ARP060100412A 2005-02-11 2006-02-06 Derivados de pirazolo -pirimidina como antagonstas de mglur2 AR052568A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05101027 2005-02-11

Publications (1)

Publication Number Publication Date
AR052568A1 true AR052568A1 (es) 2007-03-21

Family

ID=36090752

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100412A AR052568A1 (es) 2005-02-11 2006-02-06 Derivados de pirazolo -pirimidina como antagonstas de mglur2

Country Status (18)

Country Link
US (1) US7361659B2 (es)
EP (1) EP1851225B1 (es)
JP (1) JP4708438B2 (es)
KR (1) KR100968291B1 (es)
CN (1) CN101115755B (es)
AR (1) AR052568A1 (es)
AT (1) ATE512966T1 (es)
AU (1) AU2006212457B2 (es)
BR (1) BRPI0607927A2 (es)
CA (1) CA2597608C (es)
ES (1) ES2365406T3 (es)
IL (1) IL184712A (es)
MX (1) MX2007009106A (es)
NO (1) NO20073876L (es)
RU (1) RU2402553C2 (es)
TW (1) TW200716120A (es)
WO (1) WO2006084634A1 (es)
ZA (1) ZA200706353B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2085398A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2268645B1 (en) * 2008-03-06 2014-11-12 Sanofi Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof as allosteric modulators of mglur
US8207181B2 (en) 2008-03-06 2012-06-26 Sanofi Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof
US20130137865A1 (en) 2010-08-11 2013-05-30 Taisho Pharmaceutical Co., Ltd. Heteroaryl-pyrazole derivative
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
US9957271B2 (en) 2011-10-20 2018-05-01 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
EP2925292A1 (en) 2012-10-23 2015-10-07 F. Hoffmann-La Roche AG Mglu2/3 antagonists for the treatment of autistic disorders
RU2016144702A (ru) 2014-04-23 2018-05-24 Ф. Хоффманн-Ля Рош Аг Антагонисты mglu2/3 для лечения интеллектуальной недостаточности
JOP20150179B1 (ar) * 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
WO2016073889A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
SI3215511T1 (sl) 2014-11-06 2024-07-31 Bial-R&D Investments, S. A. Substituirani pirazolo(1,5-a)pirimidini in njihova uporaba pri zdravljenju zdravstvenih motenj
WO2016073891A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
AU2015357169B2 (en) 2014-12-03 2021-03-04 Janssen Pharmaceutica Nv Radiolabelled mGluR2 PET ligands
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
US11045562B2 (en) 2015-12-18 2021-06-29 Janssen Pharmaceutica Nv Radiolabelled mGluR2/3 PET ligands
JP6927974B2 (ja) 2015-12-18 2021-09-01 ヤンセン ファーマシューティカ エヌ.ベー. 放射性標識mGluR2/3PETリガンド
BR112018070586A8 (pt) * 2016-04-06 2023-03-14 Lysosomal Therapeutics Inc Compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
WO2017176961A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
BR112018072552A8 (pt) 2016-05-05 2023-03-14 Lysosomal Therapeutics Inc Compostos de imidazo [1,2-b]piridazinas e imidazo [1,5-b] piridazinas substituídas, composição farmacêutica que os compreende e seu uso no tratamento de distúrbios médicos
CN110225781B (zh) * 2017-01-09 2022-05-17 辉诺生物医药科技(杭州)有限公司 噻唑衍生物及其应用
AU2018373464B2 (en) 2017-11-24 2022-12-08 Sumitomo Pharma Co., Ltd. 6,7-dihydropyrazolo[1,5-a] pyrazinone derivative and medical use thereof
AU2019297214B2 (en) * 2018-07-06 2022-07-07 Phaeno Therapeutics Co., Ltd. Crystal forms of thiazole compound and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1090189C (zh) 1996-02-07 2002-09-04 詹森药业有限公司 吡唑并嘧啶类化合物
DK0891978T3 (da) 1997-07-18 2002-07-01 Hoffmann La Roche 5H-Thiazol(3,2-a)pyrimidinderivativer
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
HUP0400851A3 (en) * 2001-04-12 2010-03-29 Hoffmann La Roche Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists ii, process for their preparation and pharmaceutical compositions containing them
JP2006523707A (ja) * 2003-04-15 2006-10-19 アストラゼネカ アクツィエボラーグ 治療化合物
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
JP4608542B2 (ja) * 2004-06-21 2011-01-12 エフ.ホフマン−ラ ロシュ アーゲー ピラゾロピリミジン誘導体

Also Published As

Publication number Publication date
EP1851225A1 (en) 2007-11-07
MX2007009106A (es) 2007-09-11
US20060183756A1 (en) 2006-08-17
ZA200706353B (en) 2009-09-30
CA2597608A1 (en) 2006-08-17
EP1851225B1 (en) 2011-06-15
NO20073876L (no) 2007-09-10
ES2365406T3 (es) 2011-10-04
RU2402553C2 (ru) 2010-10-27
ATE512966T1 (de) 2011-07-15
JP4708438B2 (ja) 2011-06-22
AU2006212457A1 (en) 2006-08-17
IL184712A (en) 2013-05-30
JP2008530042A (ja) 2008-08-07
TW200716120A (en) 2007-05-01
KR100968291B1 (ko) 2010-07-07
WO2006084634A1 (en) 2006-08-17
AU2006212457B2 (en) 2011-04-14
CA2597608C (en) 2013-12-24
IL184712A0 (en) 2007-12-03
US7361659B2 (en) 2008-04-22
RU2007128624A (ru) 2009-03-20
CN101115755A (zh) 2008-01-30
CN101115755B (zh) 2013-01-16
KR20070104592A (ko) 2007-10-26
BRPI0607927A2 (pt) 2009-10-20

Similar Documents

Publication Publication Date Title
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
ES2515194T3 (es) Derivados de pirrolidina
CO6270309A2 (es) Inhibidores tetrahidropiranocromeno de gamma secretasa
AR060807A1 (es) Derivados de arilaminopiridina heteroaril - susutituidos como inhibidores de mek
ES2630079T3 (es) Moduladores de la ruta del complemento y usos de los mismos
AR073136A1 (es) Compuestos de pirrol
AR047456A1 (es) Derivados de amidas, procesos para su preparacion y uso como insecticidas
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
ECSP088431A (es) Derivados de pirazolo
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
AR053994A1 (es) Sulfonilpirrolidinas sustituidas procedimiento para su preparacion y su uso como medicamentos
AR082788A1 (es) Composiciones pesticidas y procesos de preparacion de los mismos
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
ECSP088479A (es) Derivados de oxadiazol
AR051995A1 (es) Derivados de tieno-piridina como intensificadores alostericos de gaba -b
CO6300861A2 (es) Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
AR067008A1 (es) Derivados 3- amino-6-(1- amino - etil)-tetrahidropirano
PA8795301A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
CO6321168A2 (es) Nuevos derivados de 2-amidotiadiazol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal